{"paper_id":"e8b9a17d-eb4d-470a-acae-5d83070054e2","body_text":"Abstract\nKeywords: FOXO, transcription, apoptosis, ovary, endometrium, endometriosis, cancer, therapy, Drosophila, polyubiquitination, Caenorhanditis elegans, Daf-16, FASLG, endometrial cancer\nCurrent Drug Targets\nTitle: FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract\nVolume: 12 Issue: 9\nAuthor(s): Mark Christian, Eric W.-F. Lam, Miranda S.C. Wilson and Jan J. Brosens\nAffiliation:\nKeywords: FOXO, transcription, apoptosis, ovary, endometrium, endometriosis, cancer, therapy, Drosophila, polyubiquitination, Caenorhanditis elegans, Daf-16, FASLG, endometrial cancer\nAbstract: All fundamental reproductive events in the human ovary and uterus, including ovulation, implantation and menstruation, are dependent upon profound tissue remodelling, characterized by cyclical waves of cell proliferation, differentiation, recruitment of inflammatory cells, apoptosis, tissue breakdown and regeneration. Although the rise and fall in ovarian hormones, estradiol and progesterone, orchestrate these reproductive events, FOXO transcription factors, an evolutionary conserved subfamily of forkhead transcription factors, have emerged major downstream effector molecules, capable of integrating hormonal cues with a variety of stress, growth factor and cytokine signal transduction pathways. The ability of FOXOs to regulate seemingly opposing cellular responses, ranging from cell cycle arrest and oxidative stress responses to differentiation and apoptosis, renders these transcription factors indispensable for cyclic tissue remodelling in the reproductive tract. Aberrant expression or perturbed activity of FOXO transcription factors are increasingly linked to prevalent reproductive disorders, such as endometriosis, endometrial cancer, primary ovarian insufficiency and pregnancy failure, which in turn highlights their potential as therapeutic targets.\nExport Options\nAbout this article\nCite this article as:\nChristian Mark, W.-F. Lam Eric, S.C. Wilson Miranda and J. Brosens Jan, FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract, Current Drug Targets 2011; 12 (9) . https://dx.doi.org/10.2174/138945011796150253\n| DOI https://dx.doi.org/10.2174/138945011796150253 |\nPrint ISSN 1389-4501 |\n| Publisher Name Bentham Science Publishers |\nOnline ISSN 1873-5592 |\nCall for Papers in Thematic Issues\nAI- and Multi-Omics-driven Development of Novel Therapeutics\nThis special issue focuses on the development of novel therapeutics for complex diseases driven by Artificial Intelligence (AI) and multi-omics approaches. It aims to highlight research that leverages computational strategies and large-scale omics data to accelerate the discovery, design, and optimization of effective therapeutics. Topics of interest include AI-assisted target ...read more\nEmerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention\nRecent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more\nMultitarget Agents For Complex Diseases\nThe basic principle of action of a drug is based on the model lock and key, where the highest possible affinity for a target results in no side effects. For many years, it was desirable‘one drug for one target for one disease’; however, the researchers observed that complex diseases are ...read more\nRecent Updates on the Molecular Targets of Chalcones\nChalcones are chemically alpha, beta-unsaturated ketones derived from the flavonoid family. The ease of synthesis and interactions with various molecular targets prompted greater attention in the field of medicinal chemistry. Recently, various aromatic or heteroaromatic derived chalcones showed good targets on neurological, cancer, diabetic, and inflammation, etc. The current thematic ...read more\n- Author Guidelines\n- Bentham Author Support Services (BASS)\n- Graphical Abstracts\n- Fabricating and Stating False Information\n- Research Misconduct\n- Post Publication Discussions and Corrections\n- Publishing Ethics and Rectitude\n- Increase Visibility of Your Article\n- Archiving Policies\n- Peer Review Workflow\n- Order Your Article Before Print\n- Promote Your Article\n- Manuscript Transfer Facility\n- Editorial Policies\n- Allegations from Whistleblowers\n- Announcements\nRelated Articles\nCurrent Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy\nCurrent Pharmaceutical Design Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies\nCurrent Drug Targets The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development\nCurrent Cancer Drug Targets Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer\nCurrent Pharmaceutical Design Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases\nCurrent Signal Transduction Therapy Three-Dimensional Ultrasound in Gynecology: Current Status and Future Perspectives\nCurrent Women`s Health Reviews All for Statins and Statins for All; An Update\nCurrent Pharmaceutical Design Obesity and Inflammation: Colorectal Cancer Engines\nCurrent Molecular Pharmacology Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma\nCurrent Molecular Medicine Patent Annotations\nRecent Patents on Anti-Cancer Drug Discovery Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme\nCurrent Medicinal Chemistry Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?\nCurrent Gene Therapy Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness\nCurrent Stem Cell Research & Therapy Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression\nCurrent Cancer Drug Targets Clinical Next Generation Sequencing for Precision Medicine in Cancer\nCurrent Genomics Chromatin Remodeling Agents for Cancer Therapy\nReviews on Recent Clinical Trials New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy\nCurrent Cancer Drug Targets Function of miRNA in Controlling Drug Resistance of Human Cancers\nCurrent Drug Targets Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations\nCurrent Drug Metabolism","source_license":"public-domain-us","license_restricted":false}